Brief Summary

This study focuses on identifying genetic and biochemical markers (biomarkers) that could help predict the course of COVID-19. The investigators aim to analyze samples taken from the nasopharynx (nose and throat), saliva, and blood of patients with acute respiratory tract infections who come to the Outpatient Clinic of the Department of Respiratory Diseases at the Thomayer University Hospital. The main objectives include measuring the expression of the SAA1 gene (using quantitative RT-PCR) and conducting broader gene expression analysis (using RNA sequencing) in nasopharyngeal cells. At the same time, the investigators will examine the patients' DNA to identify rare genetic variants or common polymorphisms that may influence their immune response to the virus. The goal is to relate the values of SAA expression with clinical and radiological status and outcome of the patients. The investigators hypothesize, that SAA may predict the severity of the disease, need for hospitalizastion and outcome of the patients.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

500

participants targeted

Target at P75+ for not_applicable covid19

Timeline

7mo left

Started Feb 2021

Longer than P75 for not_applicable covid19

Geographic Reach

1 country

1 active site

Status

active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

5.8 years study duration

Study Progress90%

Feb 2021Dec 2026

Study Start

First participant enrolled

February 10, 2021

Completed

2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2023

Completed

2.1 years until next milestone

First Submitted

Initial submission to the registry

August 1, 2025

Completed

12 days until next milestone

First Posted

Study publicly available on registry

August 13, 2025

Completed

1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected

Last Updated

August 17, 2025

Status Verified

August 1, 2025

Enrollment Period

2.4 years

First QC Date

August 1, 2025

Last Update Submit

August 13, 2025

Conditions

COVID-19

Keywords

COVID-19Serum Amyloid APredictive markers

Outcome Measures

Primary Outcomes (2)

The ability of SAA expression to predict clinical picture and outcome of the disease
Levels of expression of SAA are related to the risk of hospitalization for COVID-19
14 days
The ability of SAA expression to predict risk of death for COVID-19
Levels of expression of SAA are related to the risk of death
3 months